Organization
Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)
6 abstracts
Abstract
Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.Org: Personalis, Inc., Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO),
Abstract
Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.Org: Vanderbilt-Ingram Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, University of Texas MD Anderson Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV - IRCCS,
Abstract
Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial.Org: Paris Cité University, Medical University of Vienna, City of Hope National Comprehensive Cancer Center, Università degli Studi della Campania Luigi Vanvitelli, Department of Gastroenterology/Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven,
Abstract
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.Org: David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Exelixis, Inc.,
Abstract
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).Org: MD Anderson Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Asan Medical Center, Hammersmith Hospital, Imperial College, London, United Kingdom, Department of Gastroenterology/Digestive Oncology,
Abstract
Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Institut Bergonié, Aix Marseille University - Assistance Publique Hopitaux De Marseille, Université Paris Saclay,